Cancer cells Source: Dr. Cecil Fox, NCI

As part of our ongoing mini-series on small emerging companies to watch out for, we have two quite different biotechs focusing on different aspects of immunotherapy on deck today.

We look at what we know, what we recently learned and where things are likely headed in the near to medium term future.

As always, there’s good and bad news along the way, so what are the pitfalls and what’s to be cheerful or encouraged about?

To learn more and get a heads up on our latest immunotherapy coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers